Bond Screener
Sucampo Pharmaceuticals
LEI 549300YPLK5FSJFMAH24
Liquidated
Organization name
Sucampo Pharmaceuticals Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
-
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access
-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
A subsidiary of Mallinckrodt plc closed its acquisition of the company on February 13, 2018. Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally.Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.
|
General information
-
Organization nameSucampo Pharmaceuticals Inc.
-
Organization statusLiquidated
-
Address805 King Farm Boulevard Rockville, USA, 20850
